Posted by Michael Wonder on 21 Oct 2022
Akeso's ivonescimab granted breakthrough therapy designation by China NMPA for the treatment of advanced NSCLC
20 October 2022 - Akeso announced that the Center for Drug Evaluation of China NMPA has granted breakthrough therapy designation for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy for treatment of advanced non-small-cell lung cancer patients with EGFR mutated who failed to prior EGFR-TKI treatment.
It is ivonescimab's second breakthrough therapy designation for lung cancer treatment, and NMPA granted the first one in September 2022 for the first-line treatment of non-small-cell lung cancer patients with positive PD-L1 expression.
